Evolus, Inc. (NASDAQ:EOLS) Short Interest Update

Key Points

• Evolus, Inc. has seen a significant decrease in short interest, down 20.8% in August, with 10,680,000 shares sold short as of August 15th.
• The stock's current price is $7.58, which is a 0.4% decline from the previous trading session.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Evolus, with a consensus target price of $21.25.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) was the recipient of a large decline in short interest during the month of August. As of August 15th, there was short interest totaling 10,680,000 shares, a decline of 20.8% from the July 31st total of 13,480,000 shares. Currently, 21.1% of the company's shares are sold short. Based on an average trading volume of 1,420,000 shares, the days-to-cover ratio is presently 7.5 days. Based on an average trading volume of 1,420,000 shares, the days-to-cover ratio is presently 7.5 days. Currently, 21.1% of the company's shares are sold short.

Evolus Stock Performance

Shares of EOLS stock traded down $0.32 during trading hours on Friday, reaching $7.19. 707,868 shares of the company's stock were exchanged, compared to its average volume of 864,454. Evolus has a fifty-two week low of $5.71 and a fifty-two week high of $17.82. The stock has a market capitalization of $465.05 million, a P/E ratio of -7.34 and a beta of 1.07. The business has a fifty day moving average price of $8.08 and a 200-day moving average price of $9.92. The company has a quick ratio of 1.86, a current ratio of 2.27 and a debt-to-equity ratio of 22.00.

Insider Activity

In other Evolus news, insider David Moatazedi sold 16,582 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.89, for a total transaction of $163,995.98. Following the sale, the insider owned 364,927 shares of the company's stock, valued at approximately $3,609,128.03. This trade represents a 4.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total transaction of $42,972.22. Following the sale, the chief marketing officer directly owned 89,949 shares in the company, valued at approximately $675,516.99. The trade was a 5.98% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Institutional Trading of Evolus

Several large investors have recently made changes to their positions in EOLS. Manchester Capital Management LLC bought a new position in Evolus in the second quarter valued at about $26,000. AlphaQuest LLC acquired a new stake in Evolus in the 1st quarter valued at approximately $39,000. State of Wyoming raised its position in Evolus by 988.1% in the 1st quarter. State of Wyoming now owns 3,754 shares of the company's stock valued at $45,000 after buying an additional 3,409 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company's stock valued at $68,000 after buying an additional 5,691 shares during the last quarter. Finally, Profund Advisors LLC bought a new position in Evolus in the second quarter valued at approximately $100,000. Institutional investors own 90.69% of the company's stock.

Wall Street Analyst Weigh In

EOLS has been the topic of a number of recent research reports. HC Wainwright reduced their target price on shares of Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Wall Street Zen downgraded shares of Evolus from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Needham & Company LLC reissued a "hold" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, August 6th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Evolus in a report on Monday, September 8th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.25.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.